EMPOWERING WOMEN'S SEXUAL HEALTH
"Sexual health is fundamental to the overall health and well-being of individuals, couples and families"
Want to learn more about female sexual dysfunction?
EMPOWERING WOMEN'S SEXUAL HEALTH
"Sexual health is fundamental to the overall health and well-being of individuals, couples and families"
Want to learn more about female sexual dysfunction?
Effective, convenient solutions for sexual dysfunction
Our mission is to provide women with pharmaceutical solutions for Hypoactive Sexual Desire Disorder (HSDD) & Female Sexual Interest/Arousal Disorder (FSIAD) to help them feel like themselves again.
HSDD (Hypoactive Sexual Desire Disorder) is a type of sexual dysfunction characterized by a lack of, or significantly reduced, sexual interest. As with other types of sexual dysfunction, HSDD can be distressing and can affect a person’s self-esteem, relationships, and overall well-being.
FSIAD (Female Sexual Interest/Arousal Disorder) is a category of sexual dysfunction in women which includes both HSDD and FSAD (Female Sexual Arousal Disorder), encompassing the reduced sexual desire of HSDD with the difficulty in attaining/maintaining physical excitement of FSAD.
Women's experiences with sexual dysfunction
Low desire is the most commonly reported sexual complaint among women1-4
As many as 40% of women in a relationship struggle with their sexual health5
Women’s options for sexual dysfunction treatments are more than 20 years behind options for men6
Women's sexual health is complex - treatments for HSDD & FSIAD must be more than a one-size-fits-all
Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD (or HSDD) who are relatively insensitive to sexual cues and have difficulties with arousal. Lybrido was developed from 15 years of research, and our clinical studies have shown statistically and clinically relevant improvements in women’s sexual experiences with its use.
Read more about the science behind Lybrido
Effective, convenient solutions for sexual dysfunction
Our mission is to provide women with pharmaceutical solutions for Hypoactive Sexual Desire Disorder (HSDD) & Female Sexual Interest/Arousal Disorder (FSIAD) to help them feel like themselves again.
HSDD (Hypoactive Sexual Desire Disorder) is a type of sexual dysfunction characterized by a lack of, or significantly reduced, sexual interest. As with other types of sexual dysfunction, HSDD can be distressing and can affect a person’s self-esteem, relationships, and overall well-being.
FSIAD (Female Sexual Interest/Arousal Disorder) is a category of sexual dysfunction in women which includes both HSDD and FSAD (Female Sexual Arousal Disorder), encompassing the reduced sexual desire of HSDD with the difficulty in attaining/maintaining physical excitement of FSAD.
Women's experiences with sexual dysfunction
Low desire is the most commonly reported sexual complaint among women1-4
As many as 40% of women in a relationship struggle with their sexual health5
Women’s options for sexual dysfunction treatments are more than 20 years behind options for men6
Women's sexual health is complex - treatments for HSDD & FSIAD must be more than a one-size-fits-all
Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD (or HSDD) who are relatively insensitive to sexual cues and have difficulties with arousal. Lybrido was developed from 15 years of research, and our clinical studies have shown statistically and clinically relevant improvements in women’s sexual experiences with its use.
Read more about the science behind Lybrido
Latest news
Upcoming events
ICSM 2023: 17. International Conference on Sexual Medicine
August 17-18, 2023 | Kuala Lumpur, Malaysia
Nordic Association for Clinical Sexology (NACS) Conference 2023
September 28 – October 1, 2023 | Oslo, Norway
International Society for the Study of Women’s Sexual Health (ISSWSH) Fall Course 2023
Oct 19-22, 2023 | Scottsdale, USA
- Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999 Feb 10; 281(6):537-44.
- Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T; GSSAB Investigators’ Group. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005 Jan-Feb; 17(1): 39-57.
- Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008 Nov; 112(5): 970-8.
- McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Segraves RT. Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016 Feb;13(2): 144-52.
- Lutfey KE, Link CL, Rosen RC, Wiegel M, McKinlay JB. Prevalence and correlates of sexual activity and function in women: results from the Boston Area Community Health (BACH) Survey. Arch Sex Behav 2009 Aug; 38(4): 514-27.
- FDA Drug Approval Package: Viagra. Read more
Freya Pharma Solutions B.V.
Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands